Insmed
INSM
127 hedge funds and large institutions have $1.84B invested in Insmed in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 55 increasing their positions, 33 reducing their positions, and 21 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 33
7.68% more ownership
Funds ownership: 99.11% → 106.79% (+7.7%)
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
2% less funds holding
Funds holding: 129 → 127 (-2)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
22% less capital invested
Capital invested by funds: $2.37B → $1.84B (-$524M)
66% less call options, than puts
Call options by funds: $8.16M | Put options by funds: $24.1M
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$37.7M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$24.2M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$19.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$14.4M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$11.8M |
Top Sellers
INSM Hedge Fund Activity: Q1 2018 in Review
127 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q1 2018, worth a combined $1.84B — down 22% from $2.37B a quarter earlier.
Fund positioning in INSM was balanced in Q1 2018: 21 funds opened new positions, 21 closed out, 55 added to existing stakes and 33 trimmed.
The largest buyer was OrbiMed, adding an estimated $37.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $11.8M.
- 127 institutional investors held Insmed (INSM) as of Q1 2018, down from 129 in Q4 2017.
- Funds reported $1.84B of Insmed stock for Q1 2018, down 22% quarter-over-quarter.
- 21 funds opened new Insmed positions in Q1 2018 and 21 closed out, a net change of 0 holders.
- The largest Insmed buyer in Q1 2018 was OrbiMed, an estimated $37.7M added.
- The largest Insmed seller in Q1 2018 was T. Rowe Price Associates, an estimated $11.8M sold.
Based on aggregated 13F filings for Q1 2018.